SCHEMBL19409262

SCHEMBL19409262

CCNc1ncn(CC)c1NC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGK1 P00558 2/20 0.34
KDM4E B2RXH2 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ADORA2A P29274 3/20 0.33
ADORA1 P30542 2/20 0.33
TMIGD3 P0DMS9 1/20 0.33
ADORA2B P29275 1/20 0.33
PI4KA P42356 1/20 0.33
PI4K2B Q8TCG2 1/20 0.33
PI4K2A Q9BTU6 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
CDK1 P06493 1/20 0.32
CCNB1 P14635 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
GAA P10253 2/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19409236 0.88 ADORA2A (0.34) ADORA2AADORA1TMIGD3ADORA2BPI4KA
SCHEMBL19420515 0.87 SMN1; SMN2 (0.36) PGK1KDM4ESMN1; SMN2ADORA2AADORA1
SCHEMBL19409246 0.78 SMN1; SMN2 (0.49) PGK1KDM4ESMN1; SMN2GAAPOLB
SCHEMBL19409248 0.77 ADORA2A (0.40) KDM4EADORA2AADORA1TMIGD3ADORA2B
SCHEMBL19409259 0.74 ADORA2A (0.44) ADORA2AADORA1TMIGD3ADORA2BPI4KA
SCHEMBL19409261 0.73 ADORA2A (0.43) KDM4ESMN1; SMN2ADORA2AADORA1TMIGD3
SCHEMBL19409257 0.71 ADORA2A (0.41) ADORA2AADORA1TMIGD3ADORA2BPI4KA
SCHEMBL19409225 0.69 SMN1; SMN2 (0.56) PGK1KDM4ESMN1; SMN2CDK1GAA
SCHEMBL19409235 0.69 SMN1; SMN2 (0.51) PGK1KDM4ESMN1; SMN2GAAPOLB
Hydrochloric Acid SCHEMBL7025125 0.65 SRC (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281501-A1 4,5-DIAMINOIMIDAZOLES AS NOVEL DEVELOPER-TYPE OXIDATION DYE PRECURSORS HENKEL AG & CO. KGAA (DE) 2017-10-05 US disclosed
US-20170281501-A1 4,5-DIAMINOIMIDAZOLES AS NOVEL DEVELOPER-TYPE OXIDATION DYE PRECURSORS HENKEL AG & CO. KGAA (DE) 2017-10-05 US disclosed
US-20170281501-A1 4,5-DIAMINOIMIDAZOLES AS NOVEL DEVELOPER-TYPE OXIDATION DYE PRECURSORS HENKEL AG & CO. KGAA (DE) 2017-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281501-A1 4,5-DIAMINOIMIDAZOLES AS NOVEL DEVELOPER-TYPE OXIDATION DYE PRECURSORS KRT18, DHODH, AOC1 PGK1 2072/4885KDM4E 420/4885SMN1; SMN2 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.